Distributor inventory | Tablet

Type 2 diabetes mellitus: to improve glycaemic control as an adjunct to diet and exercise, alone or in combination with other antidiabetic medicines as prescribed.

Vildagliptin is a DPP-4 inhibitor that increases incretin hormones (GLP-1, GIP). This enhances glucose-dependent insulin secretion and reduces glucagon release, lowering blood glucose with a low risk of hypoglycaemia when used without insulin/sulfonylureas.

Oral tablet. Take exactly as prescribed, preferably at the same time each day; swallow whole with water (do not crush/chew, as it is SR). Can be taken with or without food unless your doctor advises otherwise.

Headache,dizziness,nausea,diarrhoea,abdominal discomfort,upper respiratory tract infection,peripheral edema,skin rash

Not for type 1 diabetes or diabetic ketoacidosis. Monitor liver function; stop and seek medical advice if symptoms of hepatitis/jaundice occur. Use with caution in renal impairment and in elderly; dose adjustments may be needed. Rare risk of pancreatitis—seek urgent care for severe persistent abdominal pain (with/without vomiting). Hypoglycaemia risk increases if used with insulin or sulfonylureas. Inform doctor about history of heart failure, kidney disease, liver disease, or allergy to DPP-4 inhibitors.

Insulin and sulfonylureas (increased hypoglycaemia risk),ACE inhibitors (may increase risk of angioedema),thiazide diuretics/corticosteroids/sympathomimetics (may worsen glycaemic control)

Store below 25°C in a cool, dry place. Protect from moisture and direct light. Keep out of reach of children.

Galvus 50 Tablet,Zomelis 50 Tablet,Jalra 50 Tablet,Vildaday 50 Tablet,Vildagliptin 50 mg Tablet (generic)